HDAC-IN-53 NEW
| Price | $1520 | $1980 | $2500 |
| Package | 25mg | 50mg | 100mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-22 |
Product Details
| Product Name: HDAC-IN-53 | CAS No.: 2921948-27-6 |
| Supply Ability: 10g | Release date: 2025/07/22 |
Product Introduction
Bioactivity
| Name | HDAC-IN-53 |
| Description | HDAC-IN-53 is an orally active, selective inhibitor of HDAC1-3, with IC50 values of 47 nM, 125 nM, and 450 nM, respectively. It exhibits no inhibitory effects on class II HDACs (HDAC4, 5, 6, 7, 9; IC50 >10 μM). The compound induces caspase-dependent apoptosis and significantly hampers the growth of human tumor xenografts in nude mice and murine tumor growth in immune-competent mice with MC38 colon cancer [1]. |
| In vitro | HDAC-IN-53 (Compound 19h) exhibits robust antiproliferative activity against a panel of cancer cell lines, such as MC38 (IC50 = 0.66 μM) and HCT116 cells (IC50 = 0.56 μM) [1]. At concentrations ranging from 0.1 to 1 μM over 24 hours, HDAC-IN-53 induces G0/G1 cell cycle arrest in MC38 cells and G2/M cell cycle arrest in HCT116 cells [1]. Additionally, the same treatment with HDAC-IN-53 dose-dependently upregulates the expression of cleaved caspase-3 and cleaved PARP [1]. |
| In vivo | HDAC-IN-53, administered orally at doses of 60 or 120 mg/kg once daily for 15 days, exhibited antitumor activity through both direct inhibition of tumor growth and indirect immune cell-mediated antitumor effects[1]. The pharmacokinetic parameters of HDAC-IN-53 in mice are reported as follows[1]: after intravenous (IV) administration at 5 mg/kg, the time to maximum concentration (Tmax) is 0.42 hours, with a maximum concentration (Cmax) of 8129 ng/mL. The area under the curve (AUC0-t) is 5864 ng/mL∗h, and the half-life (t1/2) is 0.85 hours. In contrast, after oral administration (PO) at 20 mg/kg, Tmax is 0.42 hours, Cmax is 9558 ng/mL, AUC0-t is 15278 ng/mL∗h, t1/2 is 2.49 hours, and the bioavailability (F%) is 65.1%. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Inhibitors Related | Panobinostat | Theophylline monohydrate | Valproic acid sodium salt | Sodium 4-phenylbutyrate | Acefylline | Vorinostat | Valproic Acid | Curcumin | Parthenolide | 4-Phenylbutyric acid | Theophylline | Methyl L-histidinate dihydrochloride |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $56.00/1mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-11-09 | |
| $0.00/10mg |
VIP2Y
|
ShenZhen H&D Pharmaceutical Technology Co., LTD
|
2024-07-17 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, Massachusetts, USA
INQUIRY